Skip to main content

Table 2 Proportion of simulations where true MTD identified

From: Assessment of various continual reassessment method models for dose-escalation phase 1 oncology clinical trials: using real clinical data and simulation studies

A. Clinical trial dose toxicity curves
Dose escalation method True dose toxicity curve
AZD3514 AZD1208 AZD1480 AZD4877
3 + 3 64.9 50.5 45.5 100.0
Extended CRM Conservative 71.7 66.8 60.9 100.0
Aggressive 34.8 88.3 51.0 100.0
Step-up 57.6 88.9 60.1 100.0
Dose-Linear 36.4 98.5 60.4 100.0
Sigmoidal 71.4 66.8 68.4 100.0
O’Quigley 56.5 78.2 59.8 100.0
B. Theoretical dose toxicity curves
Dose escalation method True dose toxicity curve
Conservative Step-up Dose-linear Sigmoidal
3 + 3 33.1 22.7 36.8 46.6
Extended CRM Conservative 63.4 43.9 53.9 50.3
Aggressive 44.6 30.8 48.2 33.9
Step-up 44.5 29.8 64.2 32.6
Dose-Linear 39.7 23.6 62.7 22.8
Sigmoidal 51.7 33.0 67.8 33.2
O’Quigley 40.4 27.3 65.9 28.9
  1. The method which correctly identified the MTD of a true dose toxicity curve in the greatest percentage of simulations is italicised and emboldened. The method which correctly identified the MTD of a true dose toxicity curve in the lowest percentage of simulations is italicised and underlined